SEARCH SITE
VIRGINIA LAW PORTAL
- Code of Virginia
- Virginia Administrative Code
- Constitution of Virginia
- Charters
- Authorities
- Compacts
- Uncodified Acts
- RIS Users (account required)
SEARCHABLE DATABASES
- Bills & Resolutions
session legislation - Bill Summaries
session summaries - Reports to the General Assembly
House and Senate documents - Legislative Liaisons
State agency contacts
ACROSS SESSIONS
- Subject Index: Since 1995
- Bills & Resolutions: Since 1994
- Summaries: Since 1994
Developed and maintained by the Division of Legislative Automated Systems.
1999 SESSION
WHEREAS, over the last decade issues relating to the pharmacy services have frequently been of prime importance to policy makers in Virginia; and
WHEREAS, chief among such issues has been the practice of therapeutic interchange of chemically dissimilar drugs; and
WHEREAS, the issues relating to therapeutic interchange of chemically dissimilar drugs are involved and difficult, including medical ethics, closed formularies, pharmacy company marketing, the practice of pharmacy, the operation of the business of pharmacy, patient rights, and appropriate medical treatment; and
WHEREAS, even the matter of defining “chemically dissimilar” presents many technical and highly charged discussions; and
WHEREAS, the significant and sometimes passionate reactions raised by the issues relating to the therapeutic interchange of chemically dissimilar drugs have resulted in many legislative initiatives; and
WHEREAS, several groups outside the legislature, both formal and informal, have examined these issues and have made some recommendations; and
WHEREAS, attempts to resolve the complex and intricate issues relating to therapeutic interchange of chemically dissimilar drugs have not, however, been completely successful; now, therefore, be it
RESOLVED by the House of Delegates, the Senate concurring, That the Joint Commission on Health Care be directed to study the issues relating to therapeutic interchange of chemically dissimilar drugs. In conducting its study, the Joint Commission shall:
1. Collect data on therapeutically dissimilar drugs which may be interchanged therapeutically to assess the efficacy of this practice;
2. Solicit input from experts in pharmacy and chemical composition of drugs and the mechanisms by which drugs work in the human body to treat disease;
3. Conduct a literature search for studies of the use of therapeutically dissimilar drugs for the same or similar therapies;
4. Receive input from all stakeholders, including, but not limited to, physicians, pharmacists, insurance companies, health maintenance organizations, third-party benefit managers, managed care pharmacy organizations, physicians, patients, and manufacturers;
5. Examine other states’ laws and regulations to identify possible mechanisms for regulating the practice of therapeutic interchange of chemically dissimilar drugs;
6. Conduct a comprehensive review of the related issues at the national level;
7. Take such other actions as appear necessary and appropriate to collect sufficient data and analysis of the issues; and
8. Make recommendations concerning whether the practice of therapeutic interchange of chemically dissimilar drugs should be regulated; the components of any such regulation, if recommended; definitions of relevant terms; and the appropriate body for such regulation, if recommended.
All agencies of the Commonwealth shall provide assistance to the Joint Commission for this study, upon request.
The Joint Commission shall complete its work in time to submit its findings and recommendations to the Governor and the 2000 Session of the General Assembly as provided in the procedures of the Division of Legislative Automated Systems for the processing of legislative documents.